Inter-individual variation in flavin-containing monooxygenase 3 in livers from Japanese: Correlation with hepatic transcription factors

Drug Metabolism and Pharmacokinetics

Volumn 24, Issue 3, 2009, Pages 218-225

  Nagashima, Satomi ^a   Shimizu, Makiko ^a   Yano, Hiroshi ^a   Murayama, Norie ^a   Kumai, Toshio ^b   Kobayashi, Shinichi ^b   Guengerich, F Peter ^c   Yamazaki, Hiroshi ^a  

^a SHOWA PHARMACEUTICAL UNIVERSITY   (Japan)

^b ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Benzydamine; FMO3; HNF 4; Methyl p tolylsulfide; NF Y

Indexed keywords

ASCORBIC ACID; BENZYDAMINE; DIMETHYLANILINE MONOOXYGENASE; FLAVIN CONTAINING MONOOXYGENASE 3; HEPATOCYTE NUCLEAR FACTOR 4; MESSENGER RNA; METHYL PARA TOLYL SULFIDE; NUCLEAR FACTOR Y BOX BINDING PROTEIN; OLANZAPINE; SULFIDE; TRANS ACTING FACTOR; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; CATALYSIS; CHILD; CONTROLLED STUDY; DRUG OXIDATION; ENZYME ACTIVITY; ENZYME REPRESSION; ENZYME SUBSTRATE; FEMALE; GENE EXPRESSION REGULATION; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; JAPANESE; LIVER LEVEL; LIVER MICROSOME; MALE; NITROSATION; NITROSYLATION; NUCLEOTIDE SEQUENCE; PRESCHOOL CHILD; PROTEIN CONTENT; PROTEIN EXPRESSION; PROTEIN MODIFICATION; SCHOOL CHILD;

EID: 67049092255     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.24.218     Document Type: Article

References (28)

1. Ziegler, D. M.: An overview of the mechanism, substrate specificities, and structure of FMOs. Drug Metab. Rev., 34: 503-511 (2002).
2. Phillips, I. R. and Shephard, E. A.: Flavin-containing monooxygenases: mutations, disease and drug response. Trends Pharmacol. Sci., 29: 294-301 (2008).
3. Zhang, J. and Cashman, J. R.: Quantitive analysis of FMO gene mRNA levels in human tissues. Drug Metab. Dispos., 34: 19-26 (2006).
4. Yeung, C. K., Adman, E. T. and Rettie, A. E.: Functional characterization of genetic variants of human FMO3 associated with trimethylaminuria. Arch. Biochem. Biophys., 464: 251-259 (2007).
5. Cashman, J. R. and Zhang, J.: Human flavin-containing monooxygenases. Annu. Rev. Pharmacol. Toxicol., 46: 65-100 (2006).
6. Yamazaki, H. and Shimizu, M.: Genetic polymorphism of the flavin-containing monooxygenase 3 (FMO3) associated with trimethylaminuria (fish odor syndrome): Observations from Japanese patients. Curr. Drug Metab., 8: 487-491 (2007).
7. Overby, L. H., Carver, G. C. and Philpot, R. M.: Quantitation and kinetic properties of hepatic microsomal and recombinant flavin-containing monooxygenases 3 and 5 from humans. Chem. Biol. Interact., 106: 29-45 (1997).
8. Koukouritaki, S. B., Simpson, P., Yeung, C. K., Rettie, A. E. and Hines, R. N.: Human hepatic flavin-containing monooxygenases 1 (FMO1) and 3 (FMO3) developmental expression. Pediatr. Res., 51: 236-243 (2002).
9. Hines, R. N.: Developmental and tissue-specific expression of human flavin-containing monooxygenases 1 and 3. Expert. Opin. Drug Metab Toxicol., 2: 41-49 (2006).
10. Mitchell, S. C.: Flavin mono-oxygenase (FMO)--the 'other' oxidase. Curr. Drug Metab., 9: 280-284 (2008).
11. Zhou, J. and Shephard, E. A.: Mutation, polymorphism and perspectives for the future of human flavin-containing monooxygenase 3. Mutat. Res., 612: 165-171 (2006).
12. Koukouritaki, S. B., Poch, M. T., Cabacungan, E. T., McCarver, D. G. and Hines, R. N.: Discovery of novel flavin-containing monooxygenase 3 (FMO3) single nucleotide polymorphisms and functional analysis of upstream haplotype variants. Mol. Pharmacol., 68: 383-392 (2005).
13. Hisamuddin, I. M. and Yang, V. W.: Genetic polymorphisms of human flavin-containing monooxygenase 3: implications for drug metabolism and clinical perspectives. Pharmacogenomics., 8: 635-643 (2007).
14. Ryu, S.-D., Yi, H.-G., Cha, Y.-N., Kang, J.-H., Kang J.-S., Jeon, Y.-C., Park, H.-K., Yu, T.-M., Lee, J.-N. and Park, C.-S.: Flavin-containing monooxygenase activity can be inhibited by nitric oxide-mediated S-nitrosylation. Life Sciences, 75: 2559-2572 (2004).
15. Allerston, C. K., Shimizu, M., Fujieda, M., Shephard, E. A., Yamazaki, H. and Phillips, I. R.: Molecular evolution and balancing selection in the flavin-containing monooxygenase 3 gene (FMO3). Pharmacogenet. Genomics, 17: 827-839 (2007).
16. Shimizu, M., Murayama, N., Nagashima, S., Fujieda, M., and Yamazaki, H.: Complex mechanism underlying transcriptional control of the haplotyped flavin-containing monooxygenase 3 (FMO3) gene in Japanese: Different regulation between mutations in 5′-upstream distal region and common element in proximal region. Drug Metab. Pharmacokinet., 23: 54-58 (2008).
17. Inoue, K., Yamazaki, H., Imiya, K., Akasaka, S., Guengerich, F. P. and Shimada, T.: Relationship between CYP2C9 and 2C19 genotypes and tolbutamide methyl hydroxylation and S-mephenytoin 4′-hydroxylation activities in livers of Japanese and Caucasian populations. Pharmacogenetics, 7: 103-113 (1997).
18. Yamazaki, H., Okayama, A., Imai, N., Guengerich, F. P. and Shimizu, M.: Interindividual variation of cytochrome P450 2J2 expression and catalytic activities in liver microsomes from Japanese and Caucasian populations. Xenobiotica, 36: 1201-1209 (2006).
19. Yamazaki, H., Fujita, H., Gunji, T., Zhang, J., Kamataki, T., Cashman, J. R. and Shimizu, M.: Stop codon mutations in the flavin-containing monooxygenase 3 (FMO3) gene responsible for trimethylaminuria in a Japanese population. Mol. Genet. Metab., 90: 58-63 (2007).
20. Shimizu, M., Yano, H., Nagashima, S., Murayama, N., Zhang, J., Cashman, J. R. and Yamazaki, H.: Effect of genetic variants of the human flavin-containing monooxygenase 3 (FMO3) on N- and S-oxygenation activities. Drug Metab. Dispos., 35: 328-330 (2007).
21. Yeung, C. K. and Rettie, A. E.: Benzydamine N-oxygenation as a measure of flavin-containing monooxygenase activity. Methods Mol. Biol., 320: 157-162 (2006).
22. Stevens, J. C., Melton, R. J., Zaya, M. J. and Engel, L. C.: Expression and characterization of functional dog flavin-containing monooxygenase 1. Mol. Pharmacol., 63: 271-275 (2003).
23. Ring, B. J., Catlow, J., Lindsay, T. J., Gillespie, T., Roskos, L. K., Cerimele, B. J., Swanson, S. P., Hamman, M. A. and Wrighton, S. A.: Identification of the human cytochromes P450 responsible for the in vitro formation of the major oxidative metabolites of the antipsychotic agent olanzapine. J. Pharmacol. Exp. Ther., 276: 658-666 (1996).
24. Yanni, S. B., Annaert, P. P., Augustijns, P., Bridges, A., Gao, Y., Benjamin, D. K., Jr. and Thakker, D. R.: Role of flavin-containing monooxygenase in oxidative metabolism of voriconazole by human liver microsomes. Drug Metab. Dispos., 36: 1119-1125 (2008).
25. Morgan, E. T., Ullrich, V., Daiber, A., Schmidt, P., Takaya, N., Shoun, H., McGiff, J. C., Oyekan, A., Hanke, C. J., Campbell, W. B., Park, C. S., Kang, J. S., Yi, H. G., Cha, Y. N.,Mansuy, D. and Boucher, J. L.: Cytochromes P450 and flavin monooxygenases--targets and sources of nitric oxide. Drug Metab. Dispos., 29: 1366-1376 (2001).
26. Lattard, V., Zhang, J. and Cashman, J. R.: Alternative processing events in human FMO genes. Mol. Pharmacol, 65: 1517-1525 (2004).
27. Klick, D. E. and Hines, R. N.: Mechanisms regulating human FMO3 transcription. Drug Metab. Rev., 39: 419-442 (2007).
28. Klick, D. E., Shadley, J. D. and Hines, R. N.: Differential regulation of human hepatic flavin containing monooxygenase 3 (FMO3) by CCAAT/ enhancer-binding protein β (C/EBPβ) liver inhibitory and liver activating proteins. Biochem. Pharmacol, 76: 268-278 (2008).